A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations
Condition(s) studied
Investigational drug(s) / intervention(s)
Osimertinib: Osimertinib will be administered as 80 mg oral tablet once daily (from Day 2) until progression of disease or until a study intervention discontinuation criterion is met.
Amivantamab: Amivantamab will be administered as an IV infusion at 1050 mg (\< 80 kg body weight) or 1400mg (≥ 80 kg body weight) (in 28-day cycles: once weekly in Cycle 1 (with a split dose on Days 1 to 2) and then every 2 weeks in subsequent cycles) until progression of disease or until a study intervention discontinuation criterion is met. The first cycle dose is spilt over 2 days- 350 mg on day 1 and 700 mg \[body weight \< 80 kg\] or 1050 mg \[body weight ≥ 80 kg\] on day 2.
Study summary
This study will assess the safety and efficacy of Osimertinib with Amivantamab as First-line Treatment in Participants with Epidermal Growth Factor Receptor Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC).
Eligibility
Primary outcome measure(s)
- Number of participants with adverse events (AEs) — From screening (Day-28) to survival follow up (Approximately 52 months after the first participant is dosed)
To assess the safety and tolerability of osimertinib plus amivantamab in participants with EGFR mutation-positive, locally advanced, or metastatic NSCLC. - Progression Free Survival (PFS) — From date of first dose of study intervention until radiological disease progression or death due to any cause (Approximately 52 months after the first participant is dosed)
The time from date of first dose of study intervention until progression per RECIST 1.1 as assessed by the investigator at the local site, or death due to any cause. The analysis will include all dosed participants. All events will be included, regardless of whether the participant withdraws from therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST 1.1.
Trial sites (28)
| Facility | City | Region | Status |
|---|---|---|---|
| Research Site | Hong Kong | Hong Kong | |
| Research Site | Hong Kong | Hong Kong | |
| Research Site | Hong Kong | Hong Kong | |
| Research Site | George Town | Malaysia | |
| Research Site | Kota Bharu | Malaysia | |
| Research Site | Kuala Lumpur | Malaysia | |
| Research Site | Kuala Lumpur | Malaysia | |
| Research Site | Kuantan | Malaysia | |
| Research Site | Kuching | Malaysia | |
| Research Site | Singapore | Singapore | |
| Research Site | Singapore | Singapore | |
| Research Site | Anyang-si | South Korea | |
| Research Site | Busan | South Korea | |
| Research Site | Daegu | South Korea | |
| Research Site | Seoul | South Korea | |
| Research Site | Seoul | South Korea | |
| Research Site | Kaohsiung City | Taiwan | |
| Research Site | Taichung | Taiwan | |
| Research Site | Taichung | Taiwan | |
| Research Site | Tainan | Taiwan | |
| Research Site | Taipei | Taiwan | |
| Research Site | Taipei | Taiwan | |
| Research Site | Yunlin | Taiwan | |
| Research Site | Bangkok | Thailand | |
| Research Site | Bangkok | Thailand | |
| Research Site | Bangkok | Thailand | |
| Research Site | Chiang Mai | Thailand | |
| Research Site | Songkhla | Thailand |
On this site
📄 Tagrisso (osimertinib) drug profile →More AstraZeneca trials in Taiwan
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05801029 on ClinicalTrials.gov ↗ ← All trials in Taiwan